Agentix Corp. (AGTX)
USD 0.05
(-35.88%)
USD 0.05
(-35.88%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.37 Million USD | 0.0% |
| 2021 | -1.34 Million USD | 0.0% |
| 2019 | -143.98 Thousand USD | 99.83% |
| 2018 | -85.41 Million USD | -20489.22% |
| 2017 | -414.87 Thousand USD | -38.83% |
| 2016 | -298.84 Thousand USD | -70.64% |
| 2015 | -175.12 Thousand USD | 16.16% |
| 2014 | -208.87 Thousand USD | -317.76% |
| 2013 | -50 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -409.55 Thousand USD | -15.81% |
| 2023 Q4 | -353.63 Thousand USD | -4.43% |
| 2023 Q3 | -338.63 Thousand USD | 20.19% |
| 2023 FY | -1.37 Million USD | 0.0% |
| 2023 Q1 | -164.65 Thousand USD | 91.84% |
| 2023 Q2 | -424.33 Thousand USD | -157.71% |
| 2022 Q3 | -186.97 Thousand USD | 23.19% |
| 2022 Q1 | -173.24 Thousand USD | 75.5% |
| 2022 Q2 | -243.42 Thousand USD | -40.51% |
| 2022 Q4 | -2.01 Million USD | -978.93% |
| 2021 Q4 | -706.96 Thousand USD | -226.22% |
| 2021 FY | -1.34 Million USD | 0.0% |
| 2021 Q1 | -1.28 Million USD | -10827.66% |
| 2021 Q3 | -216.71 Thousand USD | -59451.1% |
| 2021 Q2 | -363.91 USD | 99.97% |
| 2020 Q3 | -9556.00 USD | 42.53% |
| 2020 Q4 | -11.79 Thousand USD | -23.47% |
| 2020 Q1 | -31.92 Thousand USD | 17.66% |
| 2020 Q2 | -16.62 Thousand USD | 47.92% |
| 2019 Q1 | -42.67 Million USD | -88327.88% |
| 2019 FY | -143.98 Thousand USD | 99.83% |
| 2019 Q4 | -38.77 Thousand USD | 14.45% |
| 2019 Q3 | -45.32 Thousand USD | -42.65% |
| 2019 Q2 | -31.77 Thousand USD | 99.93% |
| 2018 Q3 | -32.74 Thousand USD | 42.41% |
| 2018 Q4 | -48.26 Thousand USD | -47.4% |
| 2018 Q1 | -38.49 Thousand USD | 75.25% |
| 2018 Q2 | -56.85 Thousand USD | -47.7% |
| 2018 FY | -85.41 Million USD | -20489.22% |
| 2017 Q2 | -116.2 Thousand USD | 35.24% |
| 2017 Q1 | -179.43 Thousand USD | -52259.88% |
| 2017 Q3 | -130.24 Thousand USD | -12.08% |
| 2017 Q4 | -155.51 Thousand USD | -19.4% |
| 2017 FY | -414.87 Thousand USD | -38.83% |
| 2016 Q1 | -15.26 Thousand USD | 80.1% |
| 2016 FY | -298.84 Thousand USD | -70.64% |
| 2016 Q4 | 344.00 USD | 198.57% |
| 2016 Q2 | -25.05 Thousand USD | -64.17% |
| 2016 Q3 | -349.00 USD | 98.61% |
| 2015 Q1 | -69.24 Thousand USD | -157.58% |
| 2015 Q3 | -58.1 Thousand USD | 5.02% |
| 2015 FY | -175.12 Thousand USD | 16.16% |
| 2015 Q4 | -76.7 Thousand USD | -32.01% |
| 2015 Q2 | -61.17 Thousand USD | 11.67% |
| 2014 Q3 | -51.57 Thousand USD | 0.0% |
| 2014 FY | -208.87 Thousand USD | -317.76% |
| 2014 Q4 | -26.88 Thousand USD | 47.87% |
| 2013 FY | -50 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -2.904% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 80.32% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 102.594% |
| Nascent Biotech, Inc. | -2.08 Million USD | 34.175% |
| Rebus Holdings, Inc. | -1.02 Million USD | -34.727% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 102.11% |
| Qrons Inc. | -789.34 Thousand USD | -74.095% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -117.299% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 97.805% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -230.753% |
| Skye Bioscience, Inc. | -37.64 Million USD | 96.35% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 98.167% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 79.103% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -402.634% |
| SQZ Biotechnologies Company | -79.46 Million USD | 98.271% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 52.489% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 24.516% |
| Mesoblast Limited | -87.95 Million USD | 98.438% |
| Marizyme, Inc. | -65.34 Million USD | 97.897% |
| Genus plc | 7.9 Million USD | 117.395% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 87.383% |
| Pharming Group N.V. | -10.54 Million USD | 86.972% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 36.667% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 62.962% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 84.462% |
| ContraFect Corporation | -65.15 Million USD | 97.891% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 71.875% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 20.449% |
| IMV Inc. | -36.48 Million USD | 96.234% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 82.95% |
| MultiCell Technologies, Inc. | -380.07 USD | -361467.869% |
| ONE Bio Corp. | 8.67 Million USD | 115.838% |
| Accustem Sciences Inc. | -3.74 Million USD | 63.319% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 97.342% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -8.45% |
| Q BioMed Inc. | -2.05 Million USD | 33.034% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 63.187% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 42.281% |
| Biomind Labs Inc. | -1.21 Million USD | -13.167% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 97.699% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 55.696% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 82.612% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 29.5% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -9076.088% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 91.342% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 76.377% |
| GB Sciences, Inc. | -1.36 Million USD | -0.92% |
| Alpha Cognition Inc. | -13.77 Million USD | 90.022% |
| HST Global, Inc. | -146.21 Thousand USD | -839.889% |
| CSL Limited | 2.64 Billion USD | 100.052% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 21.687% |
| Halberd Corporation | -79.67 Thousand USD | -1624.749% |
| Enzolytics Inc. | -2.17 Million USD | 36.871% |
| Resverlogix Corp. | -3.61 Million USD | 61.933% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 56.669% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.534% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1502.256% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 119.845% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 65.411% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 54.589% |
| AVAX Technologies, Inc. | -6.41 Million USD | 78.574% |
| Zenith Capital Corp. | -10.59 Million USD | 87.031% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.561% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -5812.619% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 66.854% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -2173.655% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 31.465% |
| Kadimastem Ltd | -3.3 Million USD | 58.45% |
| Helix BioMedix, Inc. | -1.05 Million USD | -30.127% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 64.016% |
| BioStem Technologies, Inc. | -8.48 Million USD | 83.8% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -211.352% |
| LadRx Corporation | 400.44 Thousand USD | 443.173% |
| Cell Source, Inc. | -5.32 Million USD | 74.175% |
| Regen BioPharma, Inc. | 1.02 Million USD | 234.265% |
| Regen BioPharma, Inc. | 1.02 Million USD | 234.265% |
| NovAccess Global Inc. | -4.76 Million USD | 71.186% |
| Affymax, Inc. | -14.42 Million USD | 90.473% |
| Itoco Inc. | -1.86 Million USD | 26.473% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 69.067% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 17.663% |
| Mobile Lads Corp. | -2.26 Million USD | 39.283% |
| CytoDyn Inc. | -49.84 Million USD | 97.243% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -1638.781% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -502.389% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -45.955% |
| SYBLEU INC | -180.3 Thousand USD | -662.163% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 14.79% |
| International Stem Cell Corporation | -131 Thousand USD | -949.016% |
| Bioxytran, Inc. | -4.28 Million USD | 67.892% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -2432.081% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 45.689% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 97.141% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 34.995% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -75.981% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 56.622% |
| Neutra Corp. | -233.46 Thousand USD | -488.615% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 93.227% |
| PureTech Health plc | -65.69 Million USD | 97.908% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 93.538% |
| IXICO plc | -1.17 Million USD | -16.656% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 86.157% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 97.595% |
| CSL Limited | 2.64 Billion USD | 100.052% |
| Cellectis S.A. | -103.17 Million USD | 98.668% |